Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 97,231	$ 104,031	$ 194,760	$ 192,876
Operating expenses:
Research and development	11,452	12,163	22,274	27,647
Selling, general and administrative	30,124	27,052	58,985	54,704
Restructuring expenses		(282)		29
Total operating expenses	41,576	38,933	81,259	82,380
Income from operations	55,655	65,098	113,501	110,496
Other (expense) income:
Interest expense	(2,207)	(7,732)	(4,548)	(15,358)
Interest and investment income	1,018	172	1,248	368
Gain (loss) on derivatives	(681)	(3,166)	49	(776)
Other expense, net	(1,870)	(10,726)	(3,251)	(15,766)
Income before income taxes	53,785	54,372	110,250	94,730
Income tax (expense) benefit	(16,705)	336,931	(34,369)	336,499
Net income	37,080	391,303	75,881	431,229
Comprehensive income	$ 37,080	$ 391,303	$ 75,881	$ 431,229
Net income per share - basic (in dollars per share)	$ 0.24	$ 2.42	$ 0.49	$ 2.67
Net income per share - diluted (in dollars per share)	$ 0.21	$ 2.39	$ 0.42	$ 2.64
Weighted average shares used in computing net income per share - basic (in shares)	153,304	161,948	155,550	161,460
Weighted average shares used in computing net income per share - diluted (in shares)	184,876	163,495	187,315	163,134
Collaborative arrangements revenue
Revenues:
Total revenues	$ 97,231	$ 103,386	$ 194,760	$ 192,051
Sale of active pharmaceutical ingredient
Revenues:
Total revenues		$ 645		$ 825